These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Chin CT; Roe MT; Fox KA; Prabhakaran D; Marshall DA; Petitjean H; Lokhnygina Y; Brown E; Armstrong PW; White HD; Ohman EM; Am Heart J; 2010 Jul; 160(1):16-22.e1. PubMed ID: 20598967 [TBL] [Abstract][Full Text] [Related]
29. Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. Azmoon S; Angiolillo DJ Catheter Cardiovasc Interv; 2013 Feb; 81(2):232-42. PubMed ID: 22581463 [TBL] [Abstract][Full Text] [Related]
30. Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US. Lyseng-Williamson KA Am J Cardiovasc Drugs; 2012 Jun; 12(3):207-16. PubMed ID: 22583148 [TBL] [Abstract][Full Text] [Related]
31. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884 [TBL] [Abstract][Full Text] [Related]
32. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Montalescot G; Sideris G; Cohen R; Meuleman C; Bal dit Sollier C; Barthélémy O; Henry P; Lim P; Beygui F; Collet JP; Marshall D; Luo J; Petitjean H; Drouet L Thromb Haemost; 2010 Jan; 103(1):213-23. PubMed ID: 20062936 [TBL] [Abstract][Full Text] [Related]
33. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E; Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826 [TBL] [Abstract][Full Text] [Related]
35. Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions. Steiner S; Moertl D; Chen L; Coyle D; Wells GA Thromb Haemost; 2012 Aug; 108(2):318-27. PubMed ID: 22627948 [TBL] [Abstract][Full Text] [Related]
37. Oral antiplatelet therapy for the management of acute coronary syndromes: defining the role of prasugrel. Devabhakthuni S; Seybert AL Crit Care Nurse; 2011 Feb; 31(1):51-63. PubMed ID: 20592188 [TBL] [Abstract][Full Text] [Related]